# Problem Statement

## Background

The pharmaceutical industry invests billions of dollars and years of effort into clinical trials to bring new drugs to market. A typical Phase III trial runs across **200+ hospitals and clinics ("sites") simultaneously**, enrolling thousands of patients (often **5,000+ patient visits** total). Every visit is governed by a single master document called the **protocol** — it dictates exactly when each visit should occur, what dose the patient should receive, what tests must be run, and which medications are prohibited during the trial.

## The Problem

**Protocol deviations go undetected until the FDA audit**, when it's far too late to fix the underlying patterns. These deviations fall into three everyday failure patterns:

1. **Missed or mistimed visits** — a patient was due back on day 30, comes in on day 40, or doesn't show up at all
2. **Wrong dosing** — a nurse or investigator administers the wrong amount of the trial drug
3. **Banned co-medications** — a patient starts taking a drug the protocol explicitly prohibits, without anyone at the site catching the conflict

At trial scale (thousands of visits, hundreds of sites), **no human team can manually review every record in real time**. Risk managers currently rely on periodic sampling and site self-reporting — both of which miss systemic issues until they've already escalated into audit findings.

## Who is Affected

| Stakeholder | How it affects them |
|---|---|
| **Clinical trial sponsors (pharma companies)** | Bear the direct financial and timeline risk — a failed submission costs them the trial's entire investment plus years of delay |
| **Clinical Research Associates (CRAs) / Risk Managers** | The people whose actual job is to monitor site compliance — today they do this manually, sampling records site-by-site, with no systematic way to see which sites are quietly accumulating risk |
| **Site investigators & coordinators** | Often the source of deviations, usually from staff turnover, training gaps, or protocol ambiguity — not malice. They need early feedback, not just a punitive audit finding |
| **Regulators (FDA and equivalents)** | The eventual auditors — when deviations pile up undetected, it's their audit that surfaces the problem, at the worst possible time |
| **Patients** | Ultimately at risk when deviations are safety-related (wrong dose, dangerous drug interaction) — this isn't just a paperwork problem |

## Why It Matters

- **A single rejected FDA submission delays drug approval by 6–12 months**
- That delay costs the sponsor **$50–100 million**
- Deviations that affect patient safety (wrong dose, dangerous drug interaction) can cause **real physical harm**
- The current approach — periodic manual sampling — catches problems **only in hindsight**, after the damage is done

## Why Existing Solutions Fall Short

| Gap | Current Reality |
|---|---|
| **No real-time, cross-site view** | Problems are visible only after periodic monitoring visits or at audit time |
| **No standardized severity classification** | Whether a deviation is a minor paperwork slip or a genuine safety issue is judged inconsistently and manually |
| **No leading indicators** | No way to distinguish a site that's "unlucky once" from one that's systemically at risk (repeat errors, worsening trend) |
| **Slow CAPA generation** | Writing the regulatory paperwork to document and act on findings is itself a slow, manual process |
| **No conversational interface** | Risk managers can't simply ask "which sites should I worry about today?" — they have to dig through spreadsheets |

This is the gap TrialGuard AI fills: continuous, automated, auditable compliance monitoring that gives risk managers **real-time visibility before the FDA ever sees it**.
